AMP-activated protein kinase (AMPK) and its upstream kinase, LKB1, act to both monitor and restore cellular energy in response to energy depletion. Studied extensively in liver and skeletal muscle, AMPK is phosphorylated and activated by LKB1 in response to increasing AMP/ATP ratios, which occur in a variety of settings including hypoxia, nutrient starvation and redox imbalance. Interest in the roles of both AMPK and LKB1 in cancer has grown substantially, following the identification of LKB1 as the tumor suppressor gene mutated in the Peutz-Jegher familial cancer syndrome. Patients with the Peutz-Jegher syndrome harbor a single inactive LKB1 gene, and acquisition of a second inactivating lesion (loss of heterozygosity) leads to the development of the cancer in a variety of organs. Thus, the loss of AMPK activation is hypothesized to promote the development of malignancy. Conversely, pharmacological AMPK activation has recently been shown to be cytotoxic to many established human cancer cell lines in vitro and in human cancer xenograft and mouse cancer allografts. Previously, changes in cell metabolism that accompanied the malignant phenotype have largely been considered a consequence of cellular transformation. Now, AMPK and energy metabolism are linked to the development and maintenance of the malignant phenotype. These findings have led to renewed interest in AMPK and cancer cell metabolism in general as potential targets for cancer therapy.
Introduction and historical perspective
AMP-activated protein kinase (AMPK) is a member of a protein kinase family activated during energy deficiency to restore ATP levels. 1, 2 AMPK is a heterotrimeric protein composed of a catalytic a-subunit (a1 or a2) and two regulatory subunits (b and g). 2, 3 AMPK and its attendant upstream kinase LKB1, acutely regulate cellular metabolism and chronically regulate gene expression to promote catabolism while curbing anabolic pathways. [4] [5] [6] [7] LKB1 phosphorylates and activates AMPK in reponse to increases in the AMP/ATP ratio, nutrient starvation, hypoxia, changes in cellular pH and redox status, and increases in the creatine/phosphocreatine ratio. [8] [9] [10] The role of AMPK and LKB1 in cancer is best understood in the context of cancer cell metabolism and the genetic association of LKB1 and inherited cancer syndromes. One of the most consistent biochemical changes associated with cancer is its predilection for aerobic glycolysis described in the 1920s by Otto Warburg.
11 Despite access to adequate oxygen, cancer cells continue to rely on glycolysis over respiration to generate ATP. 12 Exclusive reliance on glycolysis could provide advantages to the cancer cell under hypoxic conditions, but it also belies an inflexibility regarding energy management. The inability to switch between glycolysis and respiration depending on the extracellular environment could yield strategies for cancer therapy. Recently, the convergence of molecular biology and biochemistry has refocused interest in cancer metabolism; AMPK as a transducer of cellular energetics is central to the development of cancer and may itself be a target for cancer therapy. Although the association between AMPK and cancer is relatively recent, the story actually spans three centuries, beginning with the keen observations of a surgeon in London, circa 1896. Sir John Hutchinson described a condition in twins with peculiar pigmentation and intestinal polyposis, one of whom died with intussusception. 13 This observation was not followed up until 1921, when Dr Peutz gave a complete description of a 'very remarkable case of familial polyposis of mucous membranes of intestinal tract and nasopharynx accompanied by peculiar pigmentation of skin and mucous membranes'. 14 Finally, in 1949, Jegher and his colleagues provided a detailed description of the syndrome and coined its name as the Peutz-Jegher syndrome. 15 In addition to the hamartomatous polyps of the intestine, which can cause obstruction or intussusception, these patients have an increased predilection to develop malignant tumors of the pancreas, small intestine, colon and stomach. 16 Women also have increased risk of both breast and cervical cancer. [16] [17] [18] With the advent of molecular biology, the search for a gene associated with the Peutz-Jegher syndrome culminated in 1998, with two papers that described a novel serine threonine kinase mutated in patients with the Peutz-Jegher syndrome. 19, 20 Although the function of the gene was unknown, it was the first cancer susceptibility syndrome linked to inactivating mutations in a protein kinase. 19 Finally, two papers in 2003 identified the LKB1 tumor suppressor gene as an upstream kinase of AMPK. 7, 21 Given the complexity of the AMPK signaling pathways, it is not surprising that another familial syndrome associated with the development of hamartomatous tumors occurs in patients with mutations of proteins downstream of AMPK. Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disease characterized by the appearance of hamartomatous lesions in the brain leading to seizures and mental retardation. 22, 23 Patients with TSC harbor inactivating mutations involving either TSC1 (hamartin) or TSC2 (tuberin). 24 These genes are targets of AMPK phosphorylation, which will be detailed below. 23 Studies of both PeutzJeghers and TSC have linked alterations of fundamental energy-sensing pathways to the development of human malignancy. A picture is now emerging whereby long-term changes in energy metabolism can favor the development of human cancer. Alternatively, these pathways may also provide a plethora of new targets for cancer therapies.
LKB1/AMPK and carcinogenesis
During energy depletion, when the AMP/ATP ratio rises, LKB1, the predominant AMPK kinase in mammalian cells, 25 phosphorylates and activates AMPK leading to pleiotropic effects on cellular metabolism. Overall, AMPK activation favors restoration of cellular energy through reduction in macromolecular synthesis, enhancement of glucose transport and fatty acid oxidation, 26, 27 and cell cycle arrest in proliferating cells. 28 In patients with Peutz-Jegher syndrome, inactivation of LKB1 leads to the development of cancer, and as such, LKB1 acts as a classic tumor suppressor gene. Patients with the Peutz-Jegher syndrome harbor a single inactive LKB1 gene, and acquisition of a second inactivating lesion (loss of heterozygosity) leads to the development of the cancer or tumor in a particular organ. Thus, the inability to phosphorylate and activate AMPK favors the development of cancer.
There is increasing evidence that chronic AMPK inactivation could drive cell proliferation and growth through mammalian target-of-rapamycin (mTOR) signaling. Activated AMPK phosphorylates TSC2, activating the TSC1/TSC2, inhibiting mTOR, which suppresses protein translation through reduced S6K and 4EBP1 phosphorylation. 29 Moreover, a recent study suggests that AMPK activation may directly inhibit Akt, which would inhibit growth factor signaling through mTOR. AMPK activation may also lead to a p53-mediated cell cycle arrest. 28 In a cell with intact LKB1/AMPK signaling, energy depletion would lead to a retardation of cell growth or a growth arrest until ATP levels were restored. In cells without LKB1, proliferation would not be reduced during times of reduced energy production, thus favoring dysregulated cellular proliferationFa hallmark of the malignant phenotype. Paradoxically, however, if energy depletion was severe, LKB1 null cancer cells would not undergo cell cycle arrest and would likely undergo apoptosis. These hypotheses were supported in a study where TSC null cells increased cell size under low glucose conditions but died when glucose was withdrawn. In contrast, cells with wild-type TSC reduced their size with glucose deprivation and survived glucose withdrawal. 29 In patients harboring LKB1 or TSC complex mutations, loss of heterozygosity would essentially eliminate the AMPK-dependent metabolic checkpoint for cell growth and proliferation. Chronic dysregulated cell proliferation is a well-known harbinger for progression to a fully malignant cellular phenotype.
AMPK activation in cancer cells
Although intact LKB1/AMPK signaling in normal tissues may protect against the development of cancer, in transformed cells, AMPK activation has been shown to be substantially cytotoxic to a variety of human cancer cell lines in vitro including lung, 30 prostate, 31,32 stomach, 33 liver, 34 breast 32, 35 and glial. 32 In addition, 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside, an activator of AMPK, reduced tumor growth in vivo in a rat C6 glioma allograft, 32 and in MDA-MB-231 human breast cancer xenografts. 35 The precise mechanism whereby AMPK activation induces apoptosis or growth arrest in cancer cells is complex and its understanding is incomplete. However, a picture is emerging that AMPK activation may interfere with cancer cell metabolism mediated, perhaps in large part, through the Akt oncogene. Human cancers express two common metabolic phenotypes, aerobic glycolysis 12 and lipogenesis. 36 The combination of aerobic glycolysis and increased de novo fatty acid synthesis is not a frequent finding in normal human tissues, and is largely unique to cancer cells. Activation of the Akt oncogene may be in large part responsible for this metabolic profile. Figure 1 depicts a cancer cell with an activated Akt oncogene. In the energy surfeit state, the AMP/ATP ratio is low; LKB1 is inactive, as is AMPK. Activated Akt is responsible for the translocation of hexokinase (dashed black arrow) from the cytoplasm to a site adjacent to the mitochondria, which is thought to enable increased flux through glycolysis. 37 Additionally, activated Akt inhibits the TSC1/TSC2, which in turn inhibits ras homolog enriched in brain leading to increased mTOR signaling. Increased mTOR activity enhances transcription of glycolytic enzymes, 38, 39 protein synthesis through S6K and 4EBP1 phosphorylation, and cell growth. 29 In addition to augmenting glycolysis, Akt promotes increased fatty acid synthesis by phosphorylating and activating ATP citrate lyase 40 and as a secondary consequence of increased flux through glycolysis, nucleic acid synthesis is enhanced through ribose production from the pentose phosphate pathway. A predominant function of the pentose phosphate pathway is the production of ribose that can be utilized for nucleic acid synthesis, and NADPH that provides reducing power for macromolecular synthesis, such as fatty acid synthesis (Figure 1) . In cancer cells, the pentose phosphate pathway (hexose monophosphate shunt) contributes substantially to nucleic acid synthesis, particularly when cells are stimulated by growth factors such as transforming growth factor b. 41 Thus, Akt activation provides the cancer cell with adequate substrates for de novo nucleic acid synthesis through its augmentation of glycolysis and the pentose pathway activity. Carbon that is not used for ribose synthesis proceeds through glycolysis and either exits the cell as lactate, or continues as pyruvate into the mitochondrial tricarboxylic acid cycle (Figure 1 ). There are two predominant paths for pyruvate once it enters the cancer cell. If Akt is not activated, and the cancer cell is not undergoing aerobic glycolysis, pyruvate could be ultimately oxidized to CO 2 and H 2 O. In the setting of Akt actvation and aerobic glycolysis, however, ATP citrate lyase is phosphorylated and activated (Figure 1 ). Activated ATP citrate lyase promotes the entry of pyruvate into the tricarboxylic acid cycle only to be decarboxylated to acetyl-CoA, condensed with oxaloacetate, and liberated from the tricarboxylic acid cycle as citrate. 40 After transport to the cytoplasm, citrate is metabolized back to oxaloacetate and acetyl-CoA, by ATP citrate lyase. This provides high levels of cytoplasmic acetyl-CoA, which is the major source of carbon for fatty acid synthesis. 40 Moreover, citrate is a potent feedforward allosteric activator of acetyl-CoA carboxylase, the rate-limiting enzyme for de novo fatty acid synthesis, which produces malonyl-CoA. Finally, fatty acid synthase (FAS) produces palmitate, a 16-carbon saturated fatty acid, through successive condensation, reduction and dehydration steps utilizing malonyl-CoA, acetyl-CoA and NADPH as substrates ( Figure 1 ). The endogenously synthesized fatty acids in cancer cells are predominantly utilized for structural lipids, such as membrane phospholipids rather than for energy storage as triglycerides. 42 As a result of brisk lipogenesis, the high steady-state levels of malonyl-CoA inhibit carnitine palmitoyltransferase-1, which transports long-chain acyl-CoAs into the mitochondria for oxidation, thus preventing a futile cycle of lipogenesis and subsequent fatty acid oxidation. Thus, Akt activation induces an array of anabolic processes including aerobic glycolysis, increased lipogenesis, nucleic acid synthesis and protein synthesis with reduced fatty acid oxidation. This metabolic transformation promotes and maintains the malignant phenotype. As cancers grow, regions of the tumor may extend beyond the capacity of its vasculature to provide nutrients. As a result, AMP/ATP ratios rise and LKB1 will phosphorylate and activate AMPK. AMPK activation is well known to promote catabolism while inhibiting anabolism. Lesser glycolytic activity and carbon flux translates to less carbon available for nucleic acid synthesis and citrate available for fatty acid synthesis. Moreover, pAMPK also phosphorylates and inhibits acetyl-CoA carboxylase, further inhibiting fatty acid synthesis. Resultant mTOR inhibition will also restrict new protein synthesis. Although inhibition of protein, fatty acid and nucleic acid synthesis conserves energy utilization, the lower steady-state levels of malonylCoA relieve the inhibition of carnitine palmitoyltransferase-1 allowing for the oxidation of fatty acids for ATP generation. Importantly, pAMPK also activates p53 leading to cell cycle arrest to further conserve energy and prevent the onset of cell division with inadequate energy capacity. In this scenario, physiological AMPK activation seems to be overall antiapoptotic, preserving the integrity of the cancer cell during times of energy deprivation. If nutrient supply increases, for example, the AMP/ATP ratio would fall, reducing AMPK activation and Akt would become active again. Consequently, macromolecular synthesis could resume with relief of the cell cycle block, and tumor cell growth may continue. In contrast, rapid, pharmacological activation of AMPK seems to promote cancer cell deathF in contradistinction to physiological AMPK activation. Although the mechanism(s) responsible for these diverse responses to AMPK activation are unclear, there are a number of hypothetical circumstances where pharmacological AMPK activation could be catastrophic to cellular homeostasis.
In cancer cells with inactivating p53 mutations, AMPK activation, either physiological or pharmacological could lead to apoptosis, as cell division continues without adequate macromolecular synthesis or energy generation. Pharmacological AMPK activation could lead to a rapid reduction in fatty acid synthesis with increased levels of malonyl-CoA and citrate. High levels of malonyl-CoA could further inhibit fatty acid oxidation whereas high levels of citrate are known to inhibit phosphofructo-kinase-1 reducing glycolysis. The combination of reduced glycolysis and fatty acid synthesis could severely compromise ATP levels and cellular metabolism leading to cell death. Depending on its metabolic status and position in the cell cycle, any rapid alteration in fatty acid, nucleic acid or protein synthesis through pharmacological AMPK activation could provide the coup de grâce for a malignant cell.
Selective AMPK activation
Recent studies documenting the cytotoxic effects of AMPK activation on cancer cells provide compelling evidence supporting AMPK as a candidate anticancer target. As the pleiotropic effects of pharmacological AMPK activation on normal cells could be problematic, selective AMPK activation in cancer cells could provide a means to manage potential toxicity. One potential approach to selectively activate AMPK has arisen through the study of FAS inhibition in human cancer cells.
Our laboratory has been investigating the mechanisms, whereby inhibition of FAS leads to cancer cell death. Pharmacological FAS inhibition has been shown to be cytotoxic to human cancer cells both in vitro and in vivo. 36, 43 Surprisingly, the pharmacological inhibition of FAS in human ovarian cancer cells led to a rapid activation of AMPK within minutes, followed by the induction of substantial cytotoxicity. 44 Blocking AMPK activation with compound C, an AMPK inhibitor, substantially abrogated the cytotoxic effect of FAS inhibition. Thus, it seems that AMPK activation plays a substantial role in the mechanism, whereby FAS inhibition induces cytotoxicity. As high levels of FAS expression occur commonly in human cancers, but only in a limited number of human tissues, 45 FAS inhibition may selectively activate AMPK in cancer cells whereas sparing most human tissues. The fundamental observations of cancer metabolism first revealed in the 1920s are now yielding potential therapeutic targets, as their molecular mechanisms are unraveled. The metabolic management of cancer may provide a way to slow the progression of this disease and provide new strategies to augment present day endocrine and cytotoxic approaches.
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